Breaking News, Trials & Filings

INOVIO’s COVID-19 DNA Vax Effective in NHP

INO-4800 effective in protecting non-human primates from live virus challenge 13 weeks after the last vaccination.

By: Contract Pharma

Contract Pharma Staff

INOVIO’s COVID-19 DNA vaccine INO-4800 targeting SARS-CoV-2 was effective in protecting non-human primates from live virus challenge 13 weeks after the last vaccination. These protective results were mediated by memory T and B cell immune responses from INO-4800 vaccination. These results demonstrate that INO-4800 reduced viral load in both the lower lungs and nasal passages in macaques that received two doses of INO-4800 (1 mg) four weeks apart and then were challenged with live virus 13 wee...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters